Treeline Biosciences, a Massachusetts-based oncology company, revealed details about its first clinical candidates after operating in relative secrecy. The company announced a $200 million Series A extension, bringing total funding to approximately $1.1 billion. Treeline’s portfolio includes protein degraders targeting lymphoma and small molecule drugs aimed at KRAS mutations across multiple solid tumors, as well as a licensed EZH2 inhibitor for T cell lymphomas. The substantial capital empowers Treeline to pursue multiple programs with complementary timelines and risks, moving beyond typical milestone-driven biotech financing models.